Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5325625 | 1.00 | NFE2L2 (0.44) | NFE2L2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL12395416 | 0.86 | TDP1 (0.43) | NFE2L2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL4226727 | 0.86 | NFE2L2 (0.48) | NFE2L2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL5327099 | 0.85 | EPHX1 (0.44) | ALDH1A1MAPTKMT2AMEN1POLB | |
| SCHEMBL5327095 | 0.85 | EPHX1 (0.44) | ALDH1A1MAPTKMT2AMEN1POLB | |
| SCHEMBL13743683 | 0.81 | NFE2L2 (0.47) | NFE2L2ALDH1A1TDP1CYP19A1 | |
| SCHEMBL10143862 | 0.81 | NFE2L2 (0.47) | NFE2L2ALDH1A1TDP1CYP19A1 | |
| SCHEMBL2740535 | 0.80 | CACNA1B (0.51) | NFE2L2 | |
| SCHEMBL8257659 | 0.80 | CACNA1B (0.51) | NFE2L2 | |
| SCHEMBL491057 | 0.77 | CHEK1 (0.57) | KMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-11-25 | — | — | US | disclosed |
| EP-3530290-A1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-28 | — | — | EP | disclosed |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2019-08-01 | — | — | US | disclosed |
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| EP-1964577-B1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-04-13 | — | — | EP | disclosed |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| EP-1877098-B1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | CHROMA THERAPEUTICS LTD (GB) | 2013-04-24 | — | — | EP | disclosed |
| US-20090215800-A1 | Enzyme and Receptor Modulation | CHROMA THERAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| EP-1964577-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964578-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007129020-A1 | PYRIMIDINE DERIVATIVES USEFUL AS DHFR INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | NFE2L2 4417/4885ALDH1A1 942/4885MAPT 4501/4885 |
| US-20090215800-A1 | Enzyme and Receptor Modulation | CES1, HCAR1, DNPEP | NFE2L2 4417/4885ALDH1A1 942/4885MAPT 4501/4885 |
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | NFE2L2 4417/4885ALDH1A1 942/4885MAPT 4501/4885 |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | NFE2L2 4417/4885ALDH1A1 942/4885MAPT 4501/4885 |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | NFE2L2 4417/4885ALDH1A1 942/4885MAPT 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.